Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial | Zendy

Zhonghan Zhang | Zendy; Yunpeng Yang | Zendy; Ping Lu | Zendy; Xiaoqin Li | Zendy; Jianhua Chang | Zendy; Rongsheng Zheng | Zendy; Lei Zhou | Zendy; Shaoshui Chen | Zendy; Chen Xiao-pin | Zendy; Biyong Ren | Zendy; Wei Gu | Zendy; Xiaodong Jiang | Zendy; Jiyong Peng | Zendy; Miaolong Huang | Zendy; Guosheng Feng | Zendy; Peng Shen | Zendy; Qingyuan Zhang | Zendy; Baihong Zhang | Zendy; Yan Huang | Zendy; Jingdong He | Zendy; Yinglan Chen | Zendy; Jingxu Cao | Zendy; Hong Wang | Zendy; Wei Li | Zendy; Huiping Wan | Zendy; Kejun Nan | Zendy; Zijun Liao | Zendy; Cuiying Zhang | Zendy; Zhong Lin | Zendy; Diansheng Zhong | Zendy; Qing Xu | Zendy; Hailong Liu | Zendy; Tao Sun | Zendy; Yanming Deng | Zendy; Li Zhang | Zendy

Open Access

Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial

Author(s) -

Zhonghan Zhang,

Yunpeng Yang,

Ping Lu,

Xiaoqin Li,

Jianhua Chang,

Rongsheng Zheng,

Lei Zhou,

Shaoshui Chen,

Chen Xiao-pin,

Biyong Ren,

Wei Gu,

Xiaodong Jiang,

Jiyong Peng,

Miaolong Huang,

Guosheng Feng,

Peng Shen,

Qingyuan Zhang,

Baihong Zhang,

Yan Huang,

Jingdong He,

Yinglan Chen,

Jingxu Cao,

Hong Wang,

Wei Li,

Huiping Wan,

Kejun Nan,

Zijun Liao,

Cuiying Zhang,

Zhong Lin,

Diansheng Zhong,

Qing Xu,

Hailong Liu,

Tao Sun,

Yanming Deng,

Li Zhang

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2019.12.158

Subject(s) - aprepitant , antiemetic , medicine , nausea , chemotherapy induced nausea and vomiting , vomiting , palonosetron , clinical endpoint , regimen , chemotherapy , phases of clinical research , anesthesia , gastroenterology , randomized controlled trial

Single-dose intravenous fosaprepitant (150 mg) combined with palonosetron and dexamethasone was well tolerated and demonstrated noninferior control of CINV to aprepitant-based triple regimen in Chinese patients treating with cisplatin-base chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research